Prostate Cancer: An internal, solid-malignancy model for vaccine therapy

Phase 2

Completed

• Conditions: Hormone refractory prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12605000589684
• Lead Sponsor: Queensland Institute of Medical Research (QIMR)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-10-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

Prostatic Cancer confirmed by biopsy, hormone refractory disease, HLA-A2+.

Exclusion Criteria

Bone metastasis, ECOG status>1, PSA <4ng/ml, Abnormal haematologic parameters, Abnormal liver and renal function paramenters, history of autoimmune disease or immunosuppressive therapy, previous radiotherapy, protatectomy, or lymphadectomy, positive serology for HIV, Hep B or Hep C, Significant non-malignant disease, Psychiatric, addictive or any conditions which compromise ability to participate in this trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety[Measured at 20 weeks];Efficacy[Measured at 20 weeks]

Secondary Outcome Measures

Name	Time	Method
Changes in a variety of in vitro and in vivo immunological parameters correlated with clinical findings.[Assessed at 20 weeks.]